EU-US cluster on ‘rare’ diseases

| Updated on January 16, 2018

The European Medicines Agency (EMA) and the US FDA have set up a new ‘cluster’ on rare diseases to share experiences and best practices on each other’s regulatory approach to the development of medicines for these diseases.

While rare diseases are estimated to affect 30 million people in the EU and approximately the same number in the US, each disease individually concerns a limited number of patients.

Therefore, global collaboration in this area is particularly important to ensure that the limited number of studies conducted can benefit all patients regardless of where they live, the EMA said.

Published on September 30, 2016

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like